Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HIV vaccine trials: some design issues including sample size calculation

D O Dixon1, W N Rida, P E Fast

  • 1Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892.

Journal of Acquired Immune Deficiency Syndromes
|May 1, 1993
PubMed
Summary

Planning for large-scale HIV vaccine efficacy trials requires careful consideration of sample size. Key factors influencing this include HIV incidence rates and minimum acceptable vaccine efficacy, often necessitating thousands of participants.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children.

The Pediatric infectious disease journal·2001
Same author

Coping with multiple testing.

Controlled clinical trials·2001
Same author

Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control.

Vaccine·2000
Same author

Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults.

The Journal of infectious diseases·2000
Same author

Should data and safety monitoring boards share confidential interim data?

Controlled clinical trials·2000
Same author

Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial.

Journal of clinical microbiology·2000

Area of Science:

  • Clinical Trials
  • Vaccinology
  • Epidemiology

Background:

  • Anticipation of candidate human immunodeficiency virus (HIV) vaccines for efficacy testing.
  • Public health agencies are planning large-scale efficacy trials for HIV vaccines.

Purpose of the Study:

  • To discuss factors influencing sample size calculations for HIV vaccine efficacy trials.
  • To determine the necessary participant numbers for statistically significant trial outcomes.

Main Methods:

  • Analysis of factors impacting sample size, including HIV incidence and minimum acceptable vaccine efficacy.
  • Modeling of trial duration, benefit accrual, assay accuracy, participant counseling, and loss to follow-up.
  • Calculation of sample sizes under varying efficacy and incidence scenarios.

Related Experiment Videos

Main Results:

  • Sample size is highly sensitive to HIV incidence rates and the minimum acceptable vaccine efficacy.
  • Detecting 90% efficacy with 7% annual HIV risk requires 83 subjects per arm (3-year study).
  • Detecting 60% efficacy with 1% annual HIV risk requires 4,254 subjects per arm (2-year study with 5% loss to follow-up).

Conclusions:

  • Realistic assumptions indicate that HIV vaccine efficacy trials will likely require several thousand participants.
  • Careful consideration of statistical power, ethical considerations, and logistical factors is crucial for trial design.